Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Baricitinib in Relapsing Giant Cell Arteritis (GCA): A Phase II, Single-institution, Open-label Pilot Study

NCT03026504 is registered in ClinicalTrials.gov with Matthew J Koster as lead sponsor.

NCT NCT03026504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03026504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Baricitinib in Relapsing Giant Cell Arteritis (GCA): A Phase II, Single-institution, Open-label Pilot Study
Lead sponsor
Matthew J Koster
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2017
Completion date
April 12, 2021
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arteritis, giant cell